Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposideは一種のポドフィロトキシン(podophyllotoxin)半合成の派生物ですが、トポイソメラーゼ(topoisomerase)IIを抑制することを通じて、DNA合成を抑制します。

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00
JPY 114540.00
JPY 164340.00

カスタマーフィードバック(5)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposideは一種のポドフィロトキシン(podophyllotoxin)半合成の派生物ですが、トポイソメラーゼ(topoisomerase)IIを抑制することを通じて、DNA合成を抑制します。
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NH3GcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr2UXFzUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> MY[yOVk3ODJ6Mh?=
KellyCis83 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSyU2Q3UUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> NGToSJQzPTl4MEK4Ni=>
SK-N-AS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP MojUNlU6PjB{OEK=
SK-N-ASCis24 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HCXmlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= MnOyNlU6PjB{OEK=
U87 NEGwUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMVUxKM7:TR?= NEHYRVc1QCCq M1jh[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NVXjN4xXOjV5NUCyO|M>
HCT116 NGX2UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Tie|AvPS1{LkWg{txO NImwclM1QMLiaNMg MVTJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? NU\TWnVLOjV5NE[3OlM>
HT-29 NFXU[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK3fHcxNjVvMj61JO69VQ>? NIXiblA1QMLiaNMg NWG3VGVqUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= NYfh[nA1OjV5NE[3OlM>
Caco2 NGDxPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mzNFAvPS1{LkWg{txO NHTNfmU1QMLiaNMg NYHnbmF4UUN3ME23MlI3yqEEsdMgNU43QMLizszN MUmyOVc1Pjd4Mx?=
COLO 205 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS5NE42NTJwNTFOwG0> MUe0POKhcMLi MmjwTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NVWyWHNVOjV5NE[3OlM>
SW480 NIXDPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[yc5kxNjVvMj61JO69VQ>? MXG0POKhcMLi NUH5RoJJUUN3ME20MlkzyqEEsdMgNE4{O8LizszN NV7xfmtNOjV5NE[3OlM>
HEK293T NX3ofVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi1eoIyNTVizszN M1TldVQ5yqCqwrC= MV\JR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? MmDFNlU4PDZ5NkO=
Hep3B  NInoV5NHfW6ldHnvckBCe3OjeR?= NHHZW5QyOCEQvF2= Mlj5OFjDqGkEoB?= NWHIPZIxemWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? MXqyOVY{OzV4NB?=
Hep3B  MVvGeY5kfGmxbjDBd5NigQ>? M1vzSVAvOS1zMDFOwG0> NWrrc5BHOjRiaB?= NUXrVnhoe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B M2rKeVI2PjN|NU[0
HEK293 NGHaeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP6VJpSUUN3ME23MlE1yqEEsdMgNE4{PsLizszN Mk\5NlU3ODNzMkK=
DU145 M33OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHQTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP NHrHPXYzPTZyM{GyNi=>
HCT15 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLReG9NUUN3ME2wMlgyyqEEsdMgNE4xOcLizszN M2j1UVI2PjB|MUKy
T47D M3K2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfIN2lMUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN Ml\HNlU3ODNzMkK=
SMMC-7721 NEXhV2tHfW6ldHnvckBCe3OjeR?= MUW0NEDPxE1? MlX3OFghcA>? MkfqSG1UVw>? M3fESIlv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v Ml;PNlU2PDR|NkG=
MDA-MB-231 M4XEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NuKhcA>? NWnLPIg5UUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= M2PufVI2PDh4MkG5
MCF-7 M2jxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NuKhcA>? NYnCXWRUUUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= M4e0SVI2PDh4MkG5
Jurkat M1nhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnzbpI4PzMEoHi= NYjhb|BsUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= Mmm0NlU1QDZ{MUm=
HeLa MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NuKhcA>? NFHZWW9KSzVyPUOuPeKhyrIEoEKuN:Kh|ryP Mn3WNlU1QDZ{MUm=
MCF7  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5fo46PS1zMECg{txO M{CwXFch\A>? MnnSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYOyOVQ4OjZzOR?=
K562 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnOO|LDqGh? MnnBTWM2OD1yLkK5xsDPxE1? MXmyOVI5OjZ3Mx?=
K/VP.5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG3NuKhcA>? MYTJR|UxRTRwOdMg{txO M{niXFI2Ojh{NkWz
SH-EP  MkHUSpVv[3Srb36gRZN{[Xl? NX7QOYM4OjEEoN88[{9udA>? MmLLNlTDqGh? NHvSN5BqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\W6mb3flco92eyCGRWDQ M3TDclI2OjZzOUix
SCC25 M4PLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TXFI1yqCq NYnG[mtSUUN3ME20N{4{yqEEsdMgNU4yOsLizszN NHniXHAzPTJ{MEeyPS=>
CAL27 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSyOOKhcA>? NUPqcWt7UUN3ME21Nk4yyqEEsdMgNU4xQcLizszN NICyc5czPTJ{MEeyPS=>
FaDu NYLqe21sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6R3FOOjUEoHi= NUHueHBXUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> NF;FZW8zPTJ{MEeyPS=>
SCC25 M3P2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K4UFQ5yqCq NXXVRXY5UUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M2T5XlI2OjJyN{K5
CAL27 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnUcIJJPDkEoHi= MonETWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= NGrwOG8zPTJ{MEeyPS=>
FaDu NFrYTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3OT45tPDkEoHi= MVLJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? MoL1NlUzOjB5Mkm=
SCC25 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NuKhcA>? MnG2TWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NIntU2czPTJ{MEeyPS=>
CAL27 NYDmdYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e1PVczyqCq M2PPZ2lEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= MXuyOVIzODd{OR?=
FaDu NXj4[JpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0RmQ4OsLiaB?= MnvHTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP MortNlUzOjB5Mkm=
MCF-7 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;6OFjDqGkEoB?= MX3EUXNQ NGjN[GxKSzVyPUeuNuKhyrIEoECuPOKh|ryP Ml7JNlUzOTZ|N{i=
T-47D MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnYOFjDqGkEoB?= M1fLWGROW09? NYH3V3VzUUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= M2PSNFI2OjF4M{e4
MDA-MB-231 M1e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXHNZJFPDkEoHlCpC=> NUHDUHhNTE2VTx?= NF7zV45KSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= M3nRclI2OjF4M{e4
DU145 NHXy[GFCeG:ydH;zbZMhSXO|YYm= MnLPNVAuOTByIN88US=> NUnq[5NwQCCq NGnIbpBFVVOR MnzHbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NXXqb|BNOjVzNEm2PFE>
DU145 stem-like MVfBdI9xfG:|aYOgRZN{[Xl? NX3UOJJCOTBvMUCwJO69VQ>? NGnWdJo5KGh? M{fj[2ROW09? MnzDbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4PCPVI2OTR7Nkix
DU145 M{G3PGZ2dmO2aX;uJGF{e2G7 NWDYTnRxOTBvMUCwJO69VQ>? MmPPNkBp NWfHVYxrTE2VTx?= M{Lu[4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIrp[mUzPTF2OU[4NS=>
DU145 stem-like NUfMcIVQTnWwY4Tpc44hSXO|YYm= NX3TRoF7OTBvMUCwJO69VQ>? NWDaeIYxOiCq Ml7JSG1UVw>? NHzRVVRqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUGyOVE1QTZ6MR?=
UW228-3 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHNZoFHOC5yMT2zNFAh|ryP M1j3V|Q5KGh? M3\IOGROW09? NYTaRppiUUN3ME2wMlk6yqEQvF2= MUSyOVEyQTF6NR?=
NSCs M1;KVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[wNE4xOS1|MECg{txO NV72VINjPDhiaB?= MWjEUXNQ MkjLTWM2OD1yLkOtN:Kh|ryP NFPWfZUzPTFzOUG4OS=>
MKL-1  NVzmSI5OTnWwY4Tpc44hSXO|YYm= NGnHNZcyOC1zMECwJI5O NUfOclZyPCCm M{C1V4lv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w NF7qenQzPTFzNke1OC=>
MCF7 EV MoHESpVv[3Srb36gRZN{[Xl? MmTGNVAuOTByIN88US=> MYiy5qCKcA>? NEj6e25qdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NET1fWYzPTB6OEKwNy=>
MCF 7BMI1 MV\GeY5kfGmxbjDBd5NigQ>? M3jWZVExNTFyMDFOwG0> MYSy5qCKcA>? NXn6coZNcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? M2LSZlI2ODh6MkCz
MCF7 EV NVK1SIY3TnWwY4Tpc44hSXO|YYm= MnmxNVAuOTByIN88US=> M1;m[VLjiImq NHXGWI9GXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> NYnXO3VLOjVyOEiyNFM>
MCF7 BMI1 MnLzSpVv[3Srb36gRZN{[Xl? NWfzV3VKOTBvMUCwJO69VQ>? M{PzeVLjiImq NVG0cZRETVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NWnKWnNFOjVyOEiyNFM>
HepG2 M{PCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XQXWROW00EoB?= NYS0OXhZUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> NFriNYYzPTB5OEOxNS=>
MOLT-3 M2nPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPEUXNQyqB? NXfYWGRNUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> NY\Wd3p6OjVyN{izNVE>
HT1080 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7uOJUyNTFyMDFOwG0> M2T2V|QwOjRxNEigbC=> NX7j[Fk1TE2VT9Mg NHjncYFqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= MWCyOVA4QDB4NB?=
HT1080 MoS2SpVv[3Srb36gRZN{[Xl? NVT5dFhNOC5yMECxMVExOCEQvF2= MXuxMVI1KGh? M2fQ[WROW00EoB?= NHTWV3RqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MY[yOVA4QDB4NB?=
HT1080 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHKNE4xODBzLUGwNEDPxE1? MmC0NlQhcA>? NVPDNI0{TE2VT9Mg Ml;CZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= M1LmSVI2ODd6ME[0
HD-MY-Z NILVbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDWcm8zPC92OD:3NkBp M1vmemlEPTExvK6xNFAh|ryP MorzNlUxPDh{M{[=
DOHH-2 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DtelI1KGh? M4HJTWlEPTExvK6xNFAh|ryP NFS0TnAzPTB2OEKzOi=>
DOHH-2 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzQOFghcA>? NE\RPVVKSzVyPUG5MlnDqM7:TR?= NIjMS4ozPTB2OEKzOi=>
DOHH-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M376XlczKGh? MWTJR|UxRTYEoN88US=> Mn2wNlUxPDh{M{[=
REH NFHx[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPXOVEzPCCq MWXJR|UxRTBwMEK3xsDPxE1? NFvldHAzPTB2OEKzOi=>
REH MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPjTow1QCCq M3zxOWlEPTB;MD6wNVTDqM7:TR?= MUGyOVA1QDJ|Nh?=
REH M3G4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NkBp NHfoOZBKSzVyPUCuNFE2yqEQvF2= MkDqNlUxPDh{M{[=
HH M2jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxZlI1KGh? MULJR|UxRTFyND63xsDPxE1? NXu2XWpwOjVyNEiyN|Y>
HH NHuzXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFOFghcA>? NFnOR2FKSzVyPUS4MlbDqM7:TR?= M3TCb|I2ODR6MkO2
HH MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NkBp NUK0SpZNUUN3ME2xOE44yqEQvF2= NF7JR3czPTB2OEKzOi=>
HuT-78 M1HyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKzWHZMOjRiaB?= NY\MWlA1UUN3ME25MlPDqM7:TR?= M2TkUVI2ODR6MkO2
HuT-78 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfDbXY1QCCq NVXaWJpNUUN3ME20MlPDqM7:TR?= NF:3RXkzPTB2OEKzOi=>
HuT-78 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX1O|IhcA>? M2XoW2lEPTB;ND6yxsDPxE1? MnXINlUxPDh{M{[=
OPM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHqV5czPCCq MWHJR|UxRTJ2LkJCpO69VQ>? NV;CcYQ1OjVyNEiyN|Y>
OPM-2 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XDeVQ5KGh? NXTVU4ZOUUN3ME20xsDPxE1? NWn5bmtmOjVyNEiyN|Y>
OPM-2 NV;kcm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG3R3BUPzJiaB?= NXfTXo5HUUN3ME2xMlPDqM7:TR?= NGLxdVkzPTB2OEKzOi=>
RPMI-8226 M4TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXENlQhcA>? M4Pwe2lEPTB;MUC2MlbDqM7:TR?= NXfBToxUOjVyNEiyN|Y>
RPMI-8226 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHSRYszPDhiaB?= MoHmTWM2OD17MT6xxsDPxE1? MnLBNlUxPDh{M{[=
RPMI-8226 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FO|IhcA>? NVnndmNjUUN3ME2xOE46yqEQvF2= NVPTOXNNOjVyNEiyN|Y>
U-266 M2HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyOEBp M2fCUGlEPTB;OE[uNuKh|ryP MXyyOVA1QDJ|Nh?=
U-266 NYHhT|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS0PEBp Mmj1TWM2OD14OD60xsDPxE1? NYPt[Y1mOjVyNEiyN|Y>
U-266 M3nFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPtW4g4OiCq NEXRWI9KSzVyPUK3MlTDqM7:TR?= MnSzNlUxPDh{M{[=
Kelly MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPDeVdEOC1zMDFOwG0> M2nqOFczyqCq M4X3TmlEPTB;MT61NVjDqM7:TR?= MVeyOVAxQDlyMB?=
SH-SY5Y  NXv5bWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrtNE0yOCEQvF2= NIDTWm84OsLiaB?= M4TXSmlEPTB;MD63OVTDqM7:TdMg MXSyOVAxQDlyMB?=
SK-N-AS M1PXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjXblJxOC1zMDFOwG0> MlHBO|LDqGh? NHzMdlVKSzVyPUGuO|EzyqEQvF5CpC=> NGOzSlkzPTByOEmwNC=>
SK-N-DZ NH;BcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLTWmwxNTFyIN88US=> NHns[WM4OsLiaB?= MYXJR|UxRTVwNEi1xsDPxE1? NWDU[5ZlOjVyMEi5NFA>
HepG2 M4PrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\BOFjDqGh? MnWzSG1UV8Li NHz2VVBKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN MViyOFk6PjF|Nh?=
A549 NInXUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq0POKhcA>? NGq4[WtFVVORwrC= Mk\OTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= NVLQfVhZOjR7OU[xN|Y>
MCF7 M3OyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0NFQ1QMLiaB?= M1[yVWROW00EoB?= NIrKZ4FKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> MUSyOFk6PjF|Nh?=
HL-60  NITnXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DXXlczyqCq NHrpXHlKSzVyPUCuNVLjiIYQvF2= MW[yOFk6OzBzNB?=
HL-60[R] MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXy3NuKhcA>? M4\FcGlEPTB;Mz6xNwKBjc7:TR?= M3zUXVI1QTl|MEG0
MIAPACA NGXVRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr5UXUyT0l3ME2xMlMhyrFiMD6wN{DPxE1? NIP0VmMzPDl3M{iyNS=>
MCF-7 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkS5liT0l3ME2wMlI2KMLzIECuNUDPxE1? M4DtTFI1QTV|OEKx
HeLa NEH4c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HKR2dKPTB;MD62OEDDuSByLkSg{txO M4O5RVI1QTV|OEKx
MO59K  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyR3E4KGR? NUnSU3RzUUN3ME2wMlE46oDHzszN MV:yOFk2OzV4MR?=
MO59J NVnqO25KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\tZnIxPyCm MUHJR|UxRTBwMfMAie69VQ>? M1OyNFI1QTV|NU[x
ME 180 M{XQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfsR5g1QMLiaNMg M1z0XmlEPTB;OD65xsDDucLiMD6z5qCG|ryP M2n4b|I1QTV|MEK3
MCF-7 NIK4W5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LUXFQ5yqCqwrC= NULNWmt1UUN3ME2yN{46KMLzIECuN-KBjc7:TR?= M3[1W|I1QTV|MEK3
HeLa M{T0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\kc441QMLiaNMg NUDPXWFiUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= M1XXPVI1QTV|MEK3
MDA-MB-453 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LYVFQ5yqCqwrC= M{PMNmlEPTB;MUKuOUDDuSByLki15qCG|ryP MnuxNlQ6PTNyMke=
MDA-MB-231 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW0POKhcMLi M2rnVmlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= NH;ybG0zPDl3M{CyOy=>
PC-3 M{jKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rvT|Q5yqCqwrC= M3:yZ2lEPTB;MUSuOEDDuSB|LkKz5qCG|ryP M{LmdFI1QTV|MEK3
HT-29 NHXaOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrOU3k1QMLiaNMg MmjKTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP NU\KSZN4OjR7NUOwNlc>
BGC-823 M{DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn64OFjDqGkEoB?= MUnJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? M{jLd|I1Pzl|OEe3
HeLa NGXPV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[0POKhcMLi M1LoSmlEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> NFjRe4ozPDd7M{i3Oy=>
A549 M{LRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fMbVQ5yqCqwrC= Mn7yTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MWSyOFc6Ozh5Nx?=
HK-2 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1OFjDqGkEoB?= NUPkXJcxUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= NVvYUZJWOjR5OUO4O|c>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Related Antibodies

Topoisomerase信号経路図

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID